Nabsys 2.0, LLC expands its genomic diagnostic capabilities with the release of RepX, a cost-effective pipeline targeting 23 distinct disease-associated repeat expansion loci in a single run.
Nabsys announced the launch of RepX, a new product that could expand its market reach and positively impact its growth prospects.
Nabsys 2.0, LLC has unveiled RepX, a specialized analysis pipeline designed to identify up to 23 disease-associated repeat expansion loci. This low-cost diagnostic tool aims to streamline genetic testing processes and enhance the company's competitive positioning in the molecular diagnostics market.
RepX is a diagnostic pipeline designed to analyze up to 23 disease-associated repeat expansion loci in a single, cost-effective run.